



## Published Case Study: Validation Process Innovation at pioneering Molecular Diagnostics Company

August 30, 2017 12:00 PM EDT

HALIFAX, Aug. 30, 2017 /CNW/ – kneat.com, inc. (TSXV: KSI) (“Kneat” or the “Company”), is pleased to announce that the case study entitled “Validation Process Innovation in Molecular Diagnostics” was published today in the Journal of Validation Technology.

This case study highlights substantial productivity and compliance improvements that a leading and pioneering molecular diagnostics customer gained by transitioning their overall validation process from paper-based to a compliant, fully electronic system which was made possible by Kneat’s software. In addition, it demonstrates Kneat’s ability to scale into other sectors within the life sciences industry; in this case laboratory and diagnostics.

Key results of the implementation of this electronic validation system are outlined in the case study and include:

- an end-to-end electronic computer system validation process;
- a streamlined process with embedded lean methodologies;
- a truly scalable, best practice validation framework;
- increased effectiveness at meeting the heightened compliance, efficiency and schedule demands on the business;
- real-time visibility on the validation status of any system via the management dashboard;
- instant central access to all current information on all validation activities and deliverables via web browser access on any device;
- productivity and cycle time improvements; and
- an electronic system with the same look and feel as a traditional, paper-based validation system.

“Our customers continue to endorse and scale Kneat’s next generation technology to multiple processes and sites. This is made possible because their users find it easy to install and use,” stated Eddie Ryan, Chief Executive Officer of Kneat. “Using Kneat has proven to reduce data integrity issues, increase productivity and deliver a higher compliance standard.”

### About Kneat

Kneat, headquartered in Limerick, Ireland, develops and markets the next generation Kneat Gx software platform. Kneat Gx, enables an end-to-end paperless process for all validations, commissioning and qualification, production execution and quality document management. Kneat Gx allows users to electronically create, approve and execute all deliverables, manage any exceptions and post approve final deliverables in a controlled FDA Part 11/ Eudralex Annex 11 compliant platform. Users with correct permissions can see everything in real time. Customer case studies are reporting productivity improvements in excess of 100% and a higher compliance standard. [www.kneat.com](http://www.kneat.com)

### Cautionary and Forward-Looking Statements

Except for the statements of historical fact contained herein, certain information presented constitutes “forward-looking information” within the meaning of applicable Canadian securities laws. Such forward-looking information, includes, but is not limited to, the ability to generate sales of the Kneat Gx platform, the ability to build relationships with current and prospective customers, the market potential for the Kneat Gx platform, the ability to develop new features for the Kneat Gx platform, and the compliance of the Kneat Gx platform under regulatory audit and inspection. While such forward-looking statements are expressed by the Company, as stated in this release, in good faith and believed by the Company to have a reasonable basis, they are subject to important risks and uncertainties. As a result of these risks and uncertainties, the events predicted in these forward-looking statements may differ materially from actual results or events. These forward-looking statements are not guarantees of future performance, given that they involve risks and uncertainties. The Company does not undertake any obligation to release publicly revisions to any forward-looking statement, except as may be required under applicable securities laws. Investors should not assume that any lack of update to a previously issued forward-looking statement constitutes a reaffirmation of that statement. Continued reliance on forward-looking statements is at an investor’s own risk.

*Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

Sarah Oliver, CFO, kneat.com, inc., 2001-1969 Upper Water Street, Halifax, NS, B3J 3R7, T: +353 61 203826, E: [inquiry@kneat.com](mailto:inquiry@kneat.com)